A case of autoimmune pulmonary alveolar proteinosis responding to oral statin therapy

Respir Med Case Rep. 2024 May 25:50:102042. doi: 10.1016/j.rmcr.2024.102042. eCollection 2024.

Abstract

There is no approved drug treatment for autoimmune pulmonary alveolar proteinosis (APAP), although traditionally requires complex treatments such as whole lung lavage (WLL). We herein report on a 67-year-old man diagnosed with APAP. Treatment with atorvastatin (5 mg daily) resulted in significant improvement in symptoms, lung function, and computed tomography findings, with enhanced oxygenation, although serum anti-GM-CSF antibody levels remained elevated. This case suggests that the remission observed in this case could potentially be attributed to a direct effect of atorvastatin within the pulmonary alveoli. Statins may be considered as one of the treatment options for APAP.

Publication types

  • Case Reports